Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.30
BAX's Cash to Debt is ranked higher than
52% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.78 vs. BAX: 0.30 )
BAX' s 10-Year Cash to Debt Range
Min: 0.16   Max: 0.89
Current: 0.3

0.16
0.89
Equity to Asset 0.33
BAX's Equity to Asset is ranked lower than
51% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. BAX: 0.33 )
BAX' s 10-Year Equity to Asset Range
Min: 0.24   Max: 0.45
Current: 0.33

0.24
0.45
Interest Coverage 17.21
BAX's Interest Coverage is ranked higher than
66% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. BAX: 17.21 )
BAX' s 10-Year Interest Coverage Range
Min: 3.8   Max: 32.02
Current: 17.21

3.8
32.02
F-Score: 5
Z-Score: 3.09
M-Score: -2.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.48
BAX's Operating margin (%) is ranked higher than
87% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.96 vs. BAX: 17.48 )
BAX' s 10-Year Operating margin (%) Range
Min: 9.41   Max: 22.9
Current: 17.48

9.41
22.9
Net-margin (%) 13.19
BAX's Net-margin (%) is ranked higher than
86% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. BAX: 13.19 )
BAX' s 10-Year Net-margin (%) Range
Min: 4.08   Max: 17.55
Current: 13.19

4.08
17.55
ROE (%) 23.77
BAX's ROE (%) is ranked higher than
95% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. BAX: 23.77 )
BAX' s 10-Year ROE (%) Range
Min: 10.47   Max: 33.77
Current: 23.77

10.47
33.77
ROA (%) 7.78
BAX's ROA (%) is ranked higher than
83% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BAX: 7.78 )
BAX' s 10-Year ROA (%) Range
Min: 2.74   Max: 13.07
Current: 7.78

2.74
13.07
ROC (Joel Greenblatt) (%) 26.06
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. BAX: 26.06 )
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 16.72   Max: 42.95
Current: 26.06

16.72
42.95
Revenue Growth (%) 8.70
BAX's Revenue Growth (%) is ranked higher than
78% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BAX: 8.70 )
BAX' s 10-Year Revenue Growth (%) Range
Min: -17.7   Max: 9.5
Current: 8.7

-17.7
9.5
EBITDA Growth (%) 12.30
BAX's EBITDA Growth (%) is ranked higher than
81% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. BAX: 12.30 )
BAX' s 10-Year EBITDA Growth (%) Range
Min: -13.8   Max: 33
Current: 12.3

-13.8
33
EPS Growth (%) 15.30
BAX's EPS Growth (%) is ranked higher than
83% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.80 vs. BAX: 15.30 )
BAX' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 61.5
Current: 15.3

-20.6
61.5
» BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

BAX Guru Trades in Q1 2013

John Hussman 452,950 sh (+25782.9%)
Signature Select Canadian Fund 424,500 sh (+261.58%)
Jim Simons 987,200 sh (+54.54%)
Jeremy Grantham 1,416,548 sh (+37.67%)
Murray Stahl 4,272 sh (+34.68%)
Bill Nygren 1,253,000 sh (+8.67%)
Jeff Auxier 22,981 sh (+0.65%)
Tweedy Browne 2,608,989 sh (+0.2%)
Dodge & Cox 3,582 sh (unchged)
Meridian Funds 8,600 sh (unchged)
Jean-Marie Eveillard 2,000 sh (unchged)
John Rogers 38,276 sh (unchged)
Vanguard Health Care Fund 3,500,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Chris Davis 5,495 sh (unchged)
Bill Frels 1,776,452 sh (-0.51%)
John Buckingham 92,303 sh (-0.69%)
Diamond Hill Capital 1,862,474 sh (-0.78%)
Pioneer Investments 713,961 sh (-1.21%)
Scott Black 20,041 sh (-2.34%)
Manning & Napier Advisors, Inc 253,274 sh (-5.26%)
James Barrow 18,049,024 sh (-9%)
Jean-Marie Eveillard 884,900 sh (-10.15%)
Robert Olstein 63,000 sh (-12.5%)
Mario Gabelli 302,650 sh (-16.38%)
Paul Tudor Jones 2,900 sh (-32.56%)
Steven Cohen 9,325 sh (-67.05%)
» More
Q2 2013

BAX Guru Trades in Q2 2013

Ray Dalio 57,080 sh (New)
Paul Tudor Jones 383,300 sh (+13117.2%)
Steven Cohen 431,048 sh (+4522.5%)
Jim Simons 1,556,200 sh (+57.64%)
Jeremy Grantham 2,132,223 sh (+50.52%)
Jean-Marie Eveillard 1,144,312 sh (+29.32%)
John Rogers 49,271 sh (+28.73%)
John Buckingham 95,657 sh (+3.63%)
Murray Stahl 4,272 sh (unchged)
Bill Nygren 1,253,000 sh (unchged)
Meridian Funds 8,600 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Chris Davis 5,495 sh (unchged)
Jeff Auxier 22,981 sh (unchged)
Dodge & Cox 3,582 sh (unchged)
Tweedy Browne 2,607,066 sh (-0.07%)
Bill Frels 1,768,515 sh (-0.45%)
Manning & Napier Advisors, Inc 243,674 sh (-3.79%)
Robert Olstein 60,000 sh (-4.76%)
Scott Black 18,443 sh (-7.97%)
Diamond Hill Capital 1,710,635 sh (-8.15%)
Vanguard Health Care Fund 3,179,300 sh (-9.16%)
Pioneer Investments 644,399 sh (-9.74%)
Mario Gabelli 244,950 sh (-19.06%)
John Hussman 254,950 sh (-43.71%)
James Barrow 3,550,586 sh (-80.33%)
» More
Q3 2013

BAX Guru Trades in Q3 2013

Ray Dalio 251,063 sh (+339.84%)
Jeremy Grantham 2,709,258 sh (+27.06%)
Bill Nygren 1,523,000 sh (+21.55%)
Jean-Marie Eveillard 1,350,086 sh (+17.98%)
Jim Simons 1,813,000 sh (+16.5%)
Manning & Napier Advisors, Inc 256,267 sh (+5.17%)
Robert Olstein 62,000 sh (+3.33%)
John Buckingham 98,155 sh (+2.61%)
John Hussman 257,450 sh (+0.98%)
Signature Select Canadian Fund 428,400 sh (+0.92%)
Caxton Associates 400,000 sh (unchged)
Chris Davis 5,495 sh (unchged)
Murray Stahl 4,272 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Jeff Auxier 22,981 sh (unchged)
John Rogers 49,271 sh (unchged)
Vanguard Health Care Fund 3,179,300 sh (unchged)
Tweedy Browne 2,603,888 sh (-0.12%)
Diamond Hill Capital 1,707,999 sh (-0.15%)
Bill Frels 1,754,137 sh (-0.81%)
Mario Gabelli 240,900 sh (-1.65%)
Scott Black 18,079 sh (-1.97%)
Dodge & Cox 3,382 sh (-5.58%)
Pioneer Investments 538,124 sh (-16.49%)
James Barrow 2,076,268 sh (-41.52%)
Steven Cohen 90,581 sh (-78.99%)
Paul Tudor Jones 12,900 sh (-96.63%)
» More
Q4 2013

BAX Guru Trades in Q4 2013

Scott Black 158,392 sh (+776.11%)
John Rogers 61,251 sh (+24.31%)
Robert Olstein 77,000 sh (+24.19%)
Bill Frels 2,155,658 sh (+22.89%)
Jeff Auxier 25,981 sh (+13.05%)
Jeremy Grantham 2,919,918 sh (+7.78%)
John Buckingham 98,705 sh (+0.56%)
Murray Stahl 4,272 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
Chris Davis 5,495 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Bill Nygren 1,523,000 sh (unchged)
Steven Cohen Sold Out
James Barrow Sold Out
Pioneer Investments Sold Out
Tweedy Browne 2,601,953 sh (-0.07%)
Diamond Hill Capital 1,654,045 sh (-3.16%)
Mario Gabelli 227,850 sh (-5.42%)
Manning & Napier Advisors, Inc 228,450 sh (-10.85%)
Vanguard Health Care Fund 2,410,000 sh (-24.2%)
Ray Dalio 188,663 sh (-24.85%)
Jim Simons 951,600 sh (-47.51%)
Paul Tudor Jones 5,600 sh (-56.59%)
John Hussman 107,450 sh (-58.26%)
Jean-Marie Eveillard 7,600 sh (-99.44%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc.

Diamond Hill Capital Comments on Baxter International - Jan 15, 2014

Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market. 

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Oct 24, 2012

Medical supply manufacturer Baxter International, Inc. (BAX) reported solid second quarter results, which included strong volume and pricing in its antibody therapy. In addition, the company raised its dividend 34% and added $2 billion to its share repurchase capacity. Baxter is planning to add more capacity to break blood plasma into its component parts, which suggests the company is optimistic about future demand.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc.

Diamond Hill Capital Comments on Baxter International
Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market.  Read more...
'High Five' from Superinvestor James Barrow - Reductions in Second Quarter
Guru James Barrow’s Vanguard Select Value Fund outperformed the S&P 500 eight out of the last 10 years with a cumulative gain of 104%, while the S&P 500 gained 34.9%. Barrow has averaged returns of 14.97% over 12 months, according to the GuruFocus Score Board of Gurus. The recent portfolio update of Guru James Barrow, executive director of Barrow, Hanley, Mewhinney & Strauss shows 20 new stocks. Barrow lists 171 stocks with a total value of $5.95 billion and a quarter-over-quarter turnover of 9%. The firm currently manages more than $70 billion in assets. His top three sectors are financial services at 23.9%, health care at 16.8% and technology at 14.8%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.90
BAX's P/E(ttm) is ranked higher than
78% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.30 vs. BAX: 19.90 )
BAX' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 57.43
Current: 19.9

12.15
57.43
P/B 4.67
BAX's P/B is ranked lower than
54% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. BAX: 4.67 )
BAX' s 10-Year P/B Range
Min: 3.78   Max: 6.39
Current: 4.67

3.78
6.39
P/S 2.62
BAX's P/S is ranked higher than
59% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. BAX: 2.62 )
BAX' s 10-Year P/S Range
Min: 1.85   Max: 3.88
Current: 2.62

1.85
3.88
PFCF 23.87
BAX's PFCF is ranked higher than
74% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. BAX: 23.87 )
BAX' s 10-Year PFCF Range
Min: 12.81   Max: 31.47
Current: 23.87

12.81
31.47
EV-to-EBIT 17.23
BAX's EV-to-EBIT is ranked higher than
64% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.39 vs. BAX: 17.23 )
BAX' s 10-Year EV-to-EBIT Range
Min: 10   Max: 28.8
Current: 17.23

10
28.8
PEG 3.06
BAX's PEG is ranked higher than
61% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. BAX: 3.06 )
BAX' s 10-Year PEG Range
Min: 0.64   Max: 100.93
Current: 3.06

0.64
100.93
Shiller P/E 19.96
BAX's Shiller P/E is ranked higher than
85% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. BAX: 19.96 )
BAX' s 10-Year Shiller P/E Range
Min: 14.63   Max: 38.54
Current: 19.96

14.63
38.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
BAX's Dividend Yield is ranked higher than
85% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. BAX: 2.70 )
BAX' s 10-Year Dividend Yield Range
Min: 1.13   Max: 2.9
Current: 2.7

1.13
2.9
Dividend Payout 0.55
BAX's Dividend Payout is ranked higher than
52% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.33 vs. BAX: 0.55 )
BAX' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1.07
Current: 0.55

0.27
1.07
Dividend growth (3y) 17.60
BAX's Dividend growth (3y) is ranked higher than
88% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. BAX: 17.60 )
BAX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.5
Current: 17.6

0
22.5
Yield on cost (5-Year) 5.60
BAX's Yield on cost (5-Year) is ranked higher than
94% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. BAX: 5.60 )
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 6.01
Current: 5.6

2.34
6.01
Share Buyback Rate 2.60
BAX's Share Buyback Rate is ranked higher than
93% of the 218 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.50 vs. BAX: 2.60 )
BAX' s 10-Year Share Buyback Rate Range
Min: 3.5   Max: -2.7
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.11
BAX's Price/Tangible Book is ranked lower than
78% of the 227 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: 20.11 )
BAX' s 10-Year Price/Tangible Book Range
Min: 3.96   Max: 19.21
Current: 20.11

3.96
19.21
Price/DCF (Projected) 1.41
BAX's Price/DCF (Projected) is ranked higher than
68% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. BAX: 1.41 )
BAX' s 10-Year Price/DCF (Projected) Range
Min: 1.02   Max: 4.77
Current: 1.41

1.02
4.77
Price/Median PS Value 1.06
BAX's Price/Median PS Value is ranked higher than
66% of the 264 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. BAX: 1.06 )
BAX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 1.8
Current: 1.06

0.3
1.8
Price/Peter Lynch Fair Value 3.01
BAX's Price/Peter Lynch Fair Value is ranked higher than
51% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. BAX: 3.01 )
BAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.85   Max: 5.29
Current: 3.01

0.85
5.29
Price/Graham Number 4.19
BAX's Price/Graham Number is ranked lower than
65% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. BAX: 4.19 )
BAX' s 10-Year Price/Graham Number Range
Min: 1.61   Max: 5.9
Current: 4.19

1.61
5.9
Earnings Yield (Greenblatt) 5.80
BAX's Earnings Yield (Greenblatt) is ranked higher than
67% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. BAX: 5.80 )
BAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 10
Current: 5.8

3.5
10
Forward Rate of Return (Yacktman) 10.19
BAX's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.47 vs. BAX: 10.19 )
BAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 26.4
Current: 10.19

-0.9
26.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG » details
Traded in other countries:BAX.Switzerland, BTL.Germany
Baxter International Inc., is a Delaware corporation incorporated in 1931. It is a diversified healthcare company. Through its subsidiaries, it develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and also distributes products for hemodialysis (HD), which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. BioScience continues to face competitors from pharmaceutical, biotechnology and other companies. Medical Products face competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide